BL M02D1
Alternative Names: BL-M02D1; BL-M02D1-ADCLatest Information Update: 26 Oct 2023
At a glance
- Originator Sichuan Baili Pharmaceutical; SystImmune
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action TROP2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer; Non-small cell lung cancer
Highest Development Phases
- Phase II Lung cancer; Triple negative breast cancer
- Phase I/II Non-small cell lung cancer; Solid tumours
- Phase I Breast cancer; Gastrointestinal cancer
Most Recent Events
- 04 Sep 2023 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT05949619)
- 04 Sep 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT05949619)
- 16 Dec 2022 Phase-I clinical trials in Breast cancer (IV) (SystImmune pipeline, December 2022)